Setterwalls assists Fujirebio Diagnostics AB in becoming the first tenant in GoCo Health Innovation City

Setterwalls has assisted global market leader Fujirebio Diagnostics AB with its new establishment in GoCo Health Innovation City in Mölndal.

Fujirebio is a global market leading biotech company developing, producing and commercializing products for cancer diagnostics, with its main office in Tokyo, Japan. GoCo Health Innovation City is located close by Astra Zeneca’s research facility in Mölndal. It is a cluster of innovation in the fields of health, medicine development and digital health services. The area is run as a joint venture between Next Step and Vectura Fastigheter in close collaboration with Astra Zeneca, with the goal of strengthening west Sweden, as well as the whole of Sweden, in the pursuit of attracting the highest competence as well as the most innovative companies within the Life Science field. Fujirebio is, through its establishment in the area, looking forward to a cooperative environment and mutually beneficial relations between caregivers, academic research and the industry.